http://orcid.org/0000-0001-8898-7441
References
- Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–1539.
- Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376:1517–1526.
- Ridker PM, Amarenco P, Brunell R, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. Am Heart J. 2016;178:135–144.
- Giugliano RP, Mach F, Zavitz K, et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clinical Cardiology. 2017;40(2):59–65.
- Primary results of EBBINGHAUS, a cognitive study of patients enrolled in the FOURIER trial [Abstract 404-16]. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. 2017.
- Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017;69(5):471–482.
- Mefford M, Rosenson R, Cushman M, et al. PCSK9 variants and neurocognitive impairment: data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Journal of the American College of Cardiology. 2017;69(11):1652.